Switch to:

Key Ratios

New Key Statistics Module, Z-Score and F-Score
Market Cap $M48,582Revenue $M5,770Net Margin (%)6.3Z-Score1.7
Enterprise Value $M64,159EPS $-2.7Operating Margin %20.2F-Score7
P/E(ttm))99.6Cash Flow Per Share $4.9Pre-tax Margin (%)5.4Higher ROA y-yY
Price/Book9.510-y EBITDA Growth Rate %2.9Quick Ratio1.1Cash flow > EarningsY
Price/Sales6.25-y EBITDA Growth Rate %42.8Current Ratio1.4Lower Leverage y-yY
Price/Cash Flow11.8y-y EBITDA Growth Rate %164ROA % (ttm)1.8Higher Current Ratio y-yY
Dividend Yield %0Insider Buy (3m)1ROE % (ttm)10.0Less Shares Outstanding y-yN
Payout Ratio %0Shares Outstanding M336ROI % (ttm)-4.0Gross Margin Increase y-yY

Gurus Latest Trades with VRX

Number of guru portfolios checked: 84. (List those with share number changes of more than 20%, or impact to portfolio more than 0.1%)
TickerGuruDate Action
Impactdown Price Range
(Average)*
Current Price Change from Average Comment Current Shares
VRXGlenn Greenberg 2014-09-30 Add2.6%$106.73 - $130.26
($118.9)
$ 144.7322%Add 8.86%6,586,582
VRXLou Simpson 2014-09-30 Add1.01%$106.73 - $130.26
($118.9)
$ 144.7322%Add 12.4%1,815,916
VRXWallace Weitz 2014-09-30 Add0.54%$106.73 - $130.26
($118.9)
$ 144.7322%Add 9.05%1,691,525
VRXSteve Mandel 2014-09-30 Add0.46%$106.73 - $130.26
($118.9)
$ 144.7322%Add 8.89%10,985,940
VRXGeorge Soros 2014-09-30 Add0.15%$106.73 - $130.26
($118.9)
$ 144.7322%Add 32.73%626,748
VRXChris Davis 2014-09-30 Add0.15%$106.73 - $130.26
($118.9)
$ 144.7322%Add 11.91%3,529,237
VRXRuane Cunniff 2014-09-30 Add0.14%$106.73 - $130.26
($118.9)
$ 144.7322%Add 0.57%34,494,015
VRXAndreas Halvorsen 2014-09-30 Reduce-1.02%$106.73 - $130.26
($118.9)
$ 144.7322%Reduce -15.75%9,967,690
VRXLee Ainslie 2014-09-30 Reduce-0.18%$106.73 - $130.26
($118.9)
$ 144.7322%Reduce -3.7%2,527,896
VRXJoel Greenblatt 2014-09-30 Sold Out -0.01%$106.73 - $130.26
($118.9)
$ 144.7322%Sold Out0
VRXGlenn Greenberg 2014-06-30 Add2.33%$116.99 - $138.13
($127.6)
$ 144.7313%Add 8.19%6,050,442
VRXAndreas Halvorsen 2014-06-30 Add1.39%$116.99 - $138.13
($127.6)
$ 144.7313%Add 27.27%11,830,932
VRXSteve Mandel 2014-06-30 Add0.64%$116.99 - $138.13
($127.6)
$ 144.7313%Add 14.44%10,089,450
VRXLee Ainslie 2014-06-30 Add0.37%$116.99 - $138.13
($127.6)
$ 144.7313%Add 8.39%2,625,014
VRXGeorge Soros 2014-06-30 Add0.29%$116.99 - $138.13
($127.6)
$ 144.7313%Add 185.46%472,187
VRXChris Davis 2014-06-30 Add0.17%$116.99 - $138.13
($127.6)
$ 144.7313%Add 16.03%3,153,748
VRXJoel Greenblatt 2014-06-30 Buy 0.01%$116.99 - $138.13
($127.6)
$ 144.7313%New holding, 6172 sh.6,172
VRXDaniel Loeb 2014-06-30 Sold Out -0.48%$116.99 - $138.13
($127.6)
$ 144.7313%Sold Out0
VRXJohn Paulson 2014-06-30 Reduce-0.32%$116.99 - $138.13
($127.6)
$ 144.7313%Reduce -49.97%500,300
VRXWallace Weitz 2014-06-30 Reduce-0.19%$116.99 - $138.13
($127.6)
$ 144.7313%Reduce -2.91%1,551,076
Premium Real Time Picks are included for Premium Members only!!
*The price and date might not be the actual time and price at which the transactions were made. In the case of institutional owners, the date is stated as the last day of their fiscal quarter. The prices are estimates if no accurate information available. Foreign holdings may not be included.

VRX is held by these Gurus:

Ticker Guru Name Portfolio Date* Current Shares % of Shares Outstanding % of Total Assets Managed Change from Last Holdings Holding History
VRX George Soros 2014-09-30626,7480.190.61+32.73%
VRX Lou Simpson 2014-09-301,815,9160.549.2+12.4%
VRX Chris Davis 2014-09-303,529,2371.051.4+11.91%
VRX Wallace Weitz 2014-09-301,691,5250.56.5+9.05%
VRX Steve Mandel 2014-09-3010,985,9403.275.6+8.89%
VRX Glenn Greenberg 2014-09-306,586,5821.9632+8.86%
VRX John Paulson 2014-09-30520,7000.160.28+4.08%
VRX Ruane Cunniff 2014-09-3034,494,01510.2824+0.57%
VRX Jeff Ubben 2014-09-3018,923,8775.6416.6
VRX Private Capital 2014-09-30296,8710.094.6-1.19%
VRX Jean-Marie Eveillard 2014-09-301,010,8020.30.33-1.33%
VRX Lee Ainslie 2014-09-302,527,8960.754.8-3.7%
VRX Andreas Halvorsen 2014-09-309,967,6902.975.3-15.75%
VRX Joel Greenblatt 2014-09-30000Sold Out
Premium Most recent portfolio changes are included for Premium Members only!


VRX: Insider Buys/Sells

Click Here for All Insider Trades.
InsiderPosition Date Trades Shares Trade Price ($) Change (%) Details
UBBEN JEFFREY W 2014-11-24Buy210,000$142.251.74view
Chai-Onn Robert RoswellEVP, Gen. Couns. & Corp. Secy. 2014-06-23Sell10,203$121.718.92view
Mirovsky PavelPresident of Valeant Europe 2014-06-02Sell10,000$131.2510.27view
Chai-Onn Robert RoswellEVP, Gen. Couns. & Corp. Secy. 2014-05-13Sell10,000$130.0811.26view
Provencio Norma AnnDirector 2014-04-01Sell5,000$132.189.49view
Kornwasser LaizerEVP, Company Group Chairman 2014-03-21Buy2,481$134.977.23view
Chai-Onn Robert RoswellEVP, Gen. Couns. & Corp. Secy. 2014-03-17Sell5,000$141.722.12view
Provencio Norma AnnDirector 2014-03-03Sell5,000$141.622.2view
Provencio Norma AnnDirector 2014-02-03Sell5,000$136.236.24view
Kornwasser LaizerEVP, Company Group Chairman 2014-01-24Buy2,536$132.159.52view

Press Releases about VRX :

    Quarterly/Annual Reports about VRX:

    News about VRX:

    Articles On GuruFocus.com
    Wallace Weitz Buys Discovery Communications, Sells Apple in Q3 Nov 14 2014 
    Former Warren Buffett CIO Lou Simpson Buys Liberty Global, Valeant, U.S. Bancorp, Sells TE Connectiv Nov 14 2014 
    Ackman’s Pershing Group Buys Stake in Zoetis Nov 13 2014 
    Valeant Part XIII: channeling Jeff Skilling - or trying to reconstruct Valeant's balance sheet Oct 30 2014 
    Wallace Weitz's Partners Value Fund Q3 2014 Commentary Oct 16 2014 
    Ackman's Pershing Square Now Available To The Public Oct 13 2014 
    Bill Ackman and Valeant Could Sweeten Allergan Deal By $15 A Share Oct 10 2014 
    Wallace Weitz's Value Fund Q2 Commentary Oct 06 2014 
    Transcript of Ruane, Cunniff & Goldfarb Investor Day - May 16, 2014 Oct 05 2014 
    Most Held Canadian Stocks of the Second Quarter Sep 04 2014 


    More From Other Websites
    Business Highlights Nov 26 2014
    5 Ways CEOs Handle Activist Investors Nov 25 2014
    Today's Stocks Driving Success For The Drugs Industry Nov 25 2014
    Valeant Pharmaceuticals Announces FDA Approval Of ONEXTON™ Gel For The Treatment Of Acne Vulgaris Nov 25 2014
    8:03 am Valeant Pharmaceuticals announces FDA approval of ONEXTON gel for the treatment of Acne... Nov 25 2014
    JANA Partners adds a new position in Valeant Pharmaceuticals Nov 25 2014
    Valeant Pharmaceuticals Announces FDA Approval Of ONEXTON™ Gel For The Treatment Of Acne Vulgaris Nov 25 2014
    Valeant Pharmaceuticals Announces FDA Approval Of ONEXTON™ Gel For The Treatment Of Acne Vulgaris Nov 25 2014
    Ariad Pharmaceuticals (ARIA) Jumps: Stock Gains 9.7% Nov 25 2014
    JANA Partners opens a stake in Amgen Nov 24 2014
    Notable option trades in equities Nov 24 2014
    Activis, Allergan CEOs Discuss Details of Purchase Nov 24 2014
    Highlights of activist fund JANA Partners’ 3Q 13F Nov 21 2014
    What a week: Botox haze, merger Monday and The Tanned One Nov 21 2014
    After losing out over Allergan, Valeant announces $2 billion buyback Nov 21 2014
    Shire to Relocate Employees Under One Shire Program Nov 20 2014
    Synergy Pharmaceuticals Drug Fares Well in Phase II Study Nov 20 2014
    Valeant Pharmaceuticals Announces New $2 Billion Securities Repurchase Program Nov 20 2014
    Valeant Pharmaceuticals Announces New $2 Billion Securities Repurchase Program Nov 20 2014
    Valeant Pharmaceuticals Announces New $2 Billion Securities Repurchase Program Nov 20 2014
    Valeant Rises After Allergan Snub; Zeltiq In Buy Area Nov 19 2014
    Zoetis Provides 2015 Earnings Guidance Below Estimates Nov 19 2014
    Goldman Hits Motherlode in Deal Making Nov 19 2014
    Zoetis to Buy Abbott's Animal Health Assets for $255 Million Nov 18 2014
    Stocks Hit New Milestones; BitAuto Rebounds Nov 18 2014
    Actavis to spend $66 billion on Allergan Nov 17 2014
    S&P 500 edges to record on Allergan, Baker Hughes deals Nov 17 2014
    Actavis to buy Botox-maker Allergan for $66 billion Nov 17 2014
    Actavis to buy US Botox-maker Allergan for $66 billion Nov 17 2014
    Valeant Comments On Allergan Announcement Nov 17 2014
    Valeant Pharmaceuticals Completes Renovation Of U.S. Headquarters In New Jersey Nov 13 2014
    Valeant Pharmaceuticals Sends Letter To Physician Customers Nov 07 2014
    Allergan deal inches forward with court's decision Nov 04 2014
    Valeant And Pershing Square May Vote At Special Meeting Nov 04 2014
    Valeant: We'll bump Allergan offer to $200 a share Oct 27 2014
    Valeant Pharmaceuticals Reports Third Quarter 2014 Financial Results (pdf version) Oct 20 2014
    Valeant Pharmaceuticals To Announce 2014 Third Quarter Results On October 20, 2014 Oct 15 2014
    Allergan CEO resigns from Edwards Lifesciences' board Oct 03 2014
    Valeant pitches potential eye drug, research focus Sep 25 2014
    US stocks rally after strong housing report Sep 24 2014
    Allergan agrees to move forward with meeting Sep 16 2014
    Allergan sets date for special shareholder meeting Aug 27 2014
    US STOCKS-Futures slightly higher with indexes at records Aug 27 2014
    Allergan reviews meeting requests in takeover bid Aug 23 2014
    Allergan names Hindman chief financial officer Aug 18 2014
    Valeant extends takeover bid for Botox maker Allergan Aug 15 2014
    Former Barclays M&A chief Parker joins Goldman Sachs Aug 03 2014
    Allergan sues Valeant, claims fraud in buy attempt Aug 01 2014
    Valeant forecast overshadows strong quarter Jul 31 2014
    Allergan to cut 1,500 employees in restructuring Jul 21 2014
    US stocks drop as markets eye Gaza, Ukraine Jul 21 2014
    Nestle adds skincare muscle by completing Valeant deal Jul 10 2014
    Pershing Square names Allergan board candidates Jul 07 2014
    Actavis closes $28B Forest deal, names new CEO Jul 01 2014
    Pershing Square settles lawsuit with Allergan Jun 27 2014
    Allergan tells shareholders to reject Valeant deal Jun 23 2014
    Valeant launches hostile $53B bid for Allergan Jun 18 2014
    Valeant planning hostile bid for Allergan Jun 17 2014
    Morgan Stanley calls Valeant 'house of cards' in Allergan pitch Jun 16 2014
    Morgan Stanley called Valeant 'house of cards' in Allergan pitch Jun 16 2014
    Valeant plans hostile bid for Allergan Jun 10 2014
    Allergan board rebuffs latest Valeant offer Jun 10 2014
    Allergan rejects Valeant's higher takeover bid Jun 10 2014
    Dow, S&P 500 hit record closes after ISM data revision Jun 02 2014
    US STOCKS-Futures imply flat open with indexes at record levels Jun 02 2014
    US STOCKS-Futures flat with Dow, S&P at record levels Jun 02 2014
    MARKET PULSE-Acura, Daktronics, DSW, PetroLogistics, Wet Seal May 28 2014
    MARKET PULSE-Acura, Daktronics, DSW, First Solar, PetroLogistics May 28 2014
    Allergan board rejects Valeant takeover bid May 12 2014
    Allergan rejects Valeant Pharma's 'cut and slash' takeover May 12 2014
    Actavis and Valeant Announce FDA Approval for Metronidazole 1.3% Mar 25 2014
    Actavis and Valeant Announce FDA Approval for Metronidazole 1.3% Mar 25 2014
    Valeant Pharmaceuticals Reports Fourth Quarter And Full Year 2013 Financial Results Feb 27 2014
    Valeant Pharmaceuticals To Announce 2013 Fourth Quarter And Full Year Results On February 27, 2014 Feb 05 2014
    Valeant Pharmaceuticals to Acquire Precision Dermatology for $475 Million Feb 03 2014
    Valeant Pharmaceuticals Announces Approval of Retin-A Micro® Microsphere 0.08% Jan 31 2014
    Valeant Pharmaceuticals International, Inc. Completes Acquisition Of Solta Medical, Inc. Jan 23 2014
    Valeant Pharmaceuticals International, Inc. Completes Tender Offer for Solta Medical, Inc. Jan 23 2014
    Valeant Pharmaceuticals Announces New $1.5 Billion Securities Repurchase Program Jan 22 2014
    Valeant Pharmaceuticals To Present At Industry Conferences Dec 20 2013
    Valeant Pharmaceuticals To Hold Conference Call To Announce 2014 Financial Guidance Dec 13 2013
    Valeant Pharmaceuticals Announces Redemption Of The Remaining $465.5 Million Aggrerate Principal... Dec 02 2013

    Add Notes, Comments

    If you want to ask a question, or report a bug, please create a support ticket.

    User Comments

    No comment yet
    Get WordPress Plugins for easy affiliate links on Stock Tickers and Guru Names | Earn affiliate commissions by embedding GuruFocus Charts
    GuruFocus Affiliate Program: Earn up to $400 per referral. ( Learn More)
    Free 7-day Trial
    FEEDBACK